To investigate whether the addition of recombinant humanized anti-CD25 monoclonal antibody to the conventional EBV-T/NK LPD conditioning regimen can prevent acute and chronic GVHD after transplantation, improve the severity of GVHD and have a corresponding impact on other related post-transplant complications such as poor engraftment, thrombotic microvascular disease, early EBV reactivation and relapse.
Meet the diagnosis of EBV-T/NK lymphoproliferative disease (EBV-T/NK LPD) according to the ICC2022 diagnostic criteria
Plan to undergo allogeneic hematopoietic stem cell transplantation (allo HSCT) in our hospital
Age ≤ 18 years old
Sign informed consent form
The expected survival period for multiple organ failure is no more than 3 months
Not signing the informed consent form